- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03831256
PErsonalized Genomics for Prenatal Abnormalities Screening USing Maternal Blood (PEGASUS-2)
PErsonalized Genomics for Prenatal Abnormalities Screening USing Maternal Blood : Towards First Tier Screening and Beyond
This project aims to provide high- quality evidence to inform decisions by health care organisations about using first-tier non-invasive prenatal screening (NIPS) to replace traditional screening tests for trisomy 21, and potentially to screen for other fetal chromosome anomalies. We will compare the current screening approach of second-tier NIPS with the use of first-tier NIPS in a large cohort of pregnant women.
Study Overview
Status
Conditions
Detailed Description
There is some data on the performance of NIPS as a first tier screening test but our systematic review has shown that no trial comparing the effectiveness (utility) of 2nd-tier NIPS with that of first-tier NIPS has been published . Further it is important for health care decision makers to have evidence produced in Canada since the geographical context of healthcare can affect uptake as well as patient decision and thus their healthcare trajectories. There is a need for a trial that is between an explanatory trial and a pragmatic trial to provide the types of answer that we aim to document in the present state of knowledge on NIPS-based screening strategies in Canada. Our Objective is to perform a pan-Canadian large-scale comparative utility (clinical outcomes) study of first-tier NIPS (expanded or not) as compared to the new standard of care (NIPS as a 2nd tier test performed much later during pregnancy and only in high risk pregnancies).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 1P2
- Kelowna Regional Fertility Center
-
Prince Rupert, British Columbia, Canada, V8J 2A6
- Prince Rupert Regional Hospital
-
Vancouver, British Columbia, Canada, V6H 3N1
- Children's & Women's Health Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- CHU Ste-Justine
-
Québec, Quebec, Canada, G1L3L5
- CHU de Québec - Université Laval
-
Sept-Îles, Quebec, Canada, G4R 0N9
- CIUSSS Côte-Nord
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pregnant women 19 years or older wanting prenatal screening
- 10-13+6 wks determined by dating ultrasound or last menstrual period.
- Not intending to pursue self pay NIPT
Exclusion Criteria:
- Known fetal anomaly at the time of recruitment
- Multiple gestation
- Known twin demise
- Planned CVS or amnio for known genetic condition.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Standard of care (2nd tier NIPS)
For the standard-of-care arm (2nd tier NIPS) women will undergo Traditional integrated prenatal screening i.e. traditional biochemical (+/- NT) and those with a positive screen for T21 or T18 will be offered Second-tier Non-invasive prenatal screening (NIPS) (for T21, T18, T13) or Invasive prenatal testing for fetal aneuploidy. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis). |
biochemical prenatal screening with or without nuchal translucency by US
Other Names:
genomics based NIPS after a positive traditional prenatal screen
Other Names:
amniocentesis or chorionic villi sampling (CVS) |
|
Experimental: First-tier NIPS
For the intervention arm (1st tier NIPS) women will receive First-tier Non-invasive prenatal screening (NIPS) i.e. provide a blood sample between 10-13+5 weeks gestation with NIPS results within 7 - 10 days of sample collection. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. In case of a failed NIPS test (expected to be between 2% and 4% of samples), a new blood sample will be drawn for NIPS retest as well as for a traditional SIPS(serum integrated prenatal screening) or QUAD(quadruple marker prenatal screening) screen (depending on gestational age). Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis). |
amniocentesis or chorionic villi sampling (CVS) genomics based NIPS at first trimester
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gestational age at diagnosis
Time Frame: Up to 24 weeks of gestational age
|
gestational age at final result in the sub-set of participants that have received a positive NIPS result and that have been offered diagnostic testing |
Up to 24 weeks of gestational age
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gestational age at negative screening result
Time Frame: Up to 24 weeks of gestational age
|
gestational age at final result in the sub-set of participants that have received a negative screening result |
Up to 24 weeks of gestational age
|
|
Gestational age at positive screening result
Time Frame: Up to 24 weeks of gestational age
|
gestational age at final result in the sub-set of participants that have received a positive screening result |
Up to 24 weeks of gestational age
|
|
proportion of women with no results
Time Frame: Up to 24 weeks of gestational age
|
proportion of women with no NIPS result at first and second attempt |
Up to 24 weeks of gestational age
|
|
numbers of days for women with false positive result of screen to wait for result of definite test
Time Frame: Up to 24 weeks of gestational age
|
Difference between gestational age (in days) at first positive prenatal screening result and final negative screening result |
Up to 24 weeks of gestational age
|
|
Change in PROMIS-29 Score
Time Frame: At weeks of gestation 10-13, week 16 and week 22
|
The PROMIS-29 assesses seven health domains: physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and ability to participate in social roles and activities. Each of the seven domains has four questions which are scored on a five-point Likert scale. The PROMIS-29 scales will be scored using a T-score metric method available at the Assessment Center website (http://assessmentcenter.net). A score of 50 points represents the population average for each scale, and 10 points represent one standard deviation. Higher scores mean more of the specific scale's construct, which may indicate a desirable or an undesirable outcome. The assessment will be done at recruitment (10-13 weeks of gestation) and at week 16 and week 22 of gestation. |
At weeks of gestation 10-13, week 16 and week 22
|
|
Change in PROMIS Emotional Distress - Anxiety - Short Form 8a Score
Time Frame: At weeks of gestation 10-13, 16 and 22
|
The PROMIS-Anxiety short form assesses anxiety with 8 questions. The form includes 8 items and uses a scale of 1-5 (1=Never, 2=Almost never, 3= Sometimes, 4=Often, 5=Almost always). The raw score is the sum of the points for each response. A higher than average raw score indicates higher than average anxiety. A higher score represents higher levels of anxiety. The assessment will be done at recruitment (10-13 weeks of gestation) and at week 16 and week 22 of gestation. |
At weeks of gestation 10-13, 16 and 22
|
|
Patient-Reported Experience Measure (PREM) - Score
Time Frame: At 22 weeks of gestation
|
A 17-questions validated PREM questionnaire on pregnancy experience that measures three dimensions - type of prenatal care received and test results (seven questions), pregnancy visits (four questions (scales 1-5) and prenatal screening experience (six questions). A profile score by looking at frequencies of responses for each item will be used. |
At 22 weeks of gestation
|
|
gestational age at termination of pregnancy
Time Frame: Up to 24 weeks of gestational age
|
Gestational age at termination of pregnancy for participants having volountary termination |
Up to 24 weeks of gestational age
|
|
percentage of women undergoing invasive diagnostic testing
Time Frame: Up to 24 weeks of gestational age
|
see outcome title |
Up to 24 weeks of gestational age
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sylvie Langlois, MD FRCPC, University of British Columbia
- Principal Investigator: Francois Rousseau, MD MSc FRCPC, CHU de Québec - Université Laval
Publications and helpful links
General Publications
- Badeau M, Lindsay C, Blais J, Nshimyumukiza L, Takwoingi Y, Langlois S, Legare F, Giguere Y, Turgeon AF, Witteman W, Rousseau F. Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women. Cochrane Database Syst Rev. 2017 Nov 10;11(11):CD011767. doi: 10.1002/14651858.CD011767.pub2.
- Dubeau A, El Balqui M, Talbot D, Rousseau F, Langlois S, Chen W, Audibert F, Bujold E, Forest JC, Dofara SG, Legare F. Validation of PREM-PS, a patient-reported experience instrument, in a randomized controlled trial of pregnant women undergoing prenatal screening. J Patient Rep Outcomes. 2026 Mar 7;10(1):59. doi: 10.1186/s41687-026-01020-5.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SIRUL 118984
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.